VADUZ, Liechtenstein, April 26, 2024 /PRNewswire/ -- Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website.

"Implantica had a very successful and busy 2023. We are well advanced in convincing the surgical community that RefluxStop™ is the upcoming standard of care. The market for RefluxStop™ is truly massive, with 1 billion sufferers, and more than 400 million acid reflux sufferers unable to find relief from medicine. In Europe, we are clearly gaining traction with the region's top physicians and acceptance from public healthcare systems. With >750 patients successfully treated in Europe and over 30 hospitals operating, the medical system is waking up to the potential cost savings and health benefits of RefluxStop™," says Peter Forsell, CEO of Implantica.

For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on April 26, 2024, at 08:30 a.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

Newsroom

https://www.implantica.com/media/media-kit

Media Contact:
Implantica AG
Juanita Eberhart, VP Marketing & Advocacy
M: +1 925-381-4581
juanita.eberhart@implantica.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-publishes-annual-report-2023,c3968501

The following files are available for download:


     
     https://mb.cision.com/Main/19732/3968501/2761948.pdf            
     Implantica Annual Report 2023_ENG_O



     
     https://mb.cision.com/Public/19732/3968501/add4f3de6c360127.pdf   Implantica publishes Annual Report 2023
                                                                           25Apr2024 EN

View original content:https://www.prnewswire.co.uk/news-releases/implantica-publishes-annual-report-2023-302128422.html

Tags

More Like This

Implantica publishes Year-end Report, January - December 2023 (Q4)

Implantica publishes Interim Report January - September 2024 (Q3)

Implantica publishes Interim Report January - September 2023 (Q3)

Implantica publishes Interim Report January - March 2024 (Q1)

Implantica publishes Interim Report January - June 2024 (Q2)

Implantica takes a big step forward at its 2nd Annual RefluxStop™ Users Meeting

Implantica presents the third quarter 2023 on November 22 at 15:00 CET

Implantica presents the fourth quarter 2023 on February 16 at 15:00 CET